7:30 am – 8:00 am  Registration & Breakfast
8:00 am – 1:15 pm  CME/CNE Activity
With Mid-morning Break

Dates and Locations

→ Saturday, October 26, 2019 | Chicago, IL

→ Saturday, November 2, 2019 | Newport Beach, CA

→ Saturday, November 9, 2019 | Philadelphia, PA

→ Saturday, November 16, 2019 | Miami, FL

→ Saturday, December 7, 2019 | Washington, DC

Program Overview

Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. The management of patients with MS is highly complex, and the development of disease-modifying therapies (DMTs) has dramatically altered the treatment paradigm. Clinicians need to be updated on new evidence-based recommendations on the use of DMTs from the American Academy of Neurology Guidelines released in 2018. Another important aspect of caring for patients with MS is communication. Patients must be not only educated about their disease and treatment options, but also engaged in conversations about their risk tolerance, quality of life—including symptoms that they are experiencing—and any concerns they may have regarding their care. Shared decision-making is a model of two-way communication between a patient and a provider with established ability to improve a patient’s satisfaction of care. In this CME/CNE activity, MS Forum® VI, current treatment guidelines, gender-based issues, environmental factors, and comorbidities in MS will be discussed alongside the safety, efficacy, and use of current DMTs. In addition, the program will include rapid TED-like didactic presentations, video segments of a patient’s perspective of MS, and a rapid-fire panel addressing controversial topics in MS.

Target Audience

The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with MS.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

Physicians and Nurses

  • Evaluate the latest clinical and/or real-world evidence regarding available and emerging DMTs for MS management.
  • Assess the burden of comorbidities for patients with MS and implications for treatment, medication management, and quality of life.
  • Examine emerging clinical trends and controversies in MS that may impact future clinical decision making.
  • Incorporate appropriate shared decision-making strategies to engage patients with MS in their own care.

Physicians Only

  • Identify patients with RRMS or progressive MS in a timely manner to ensure appropriate intervention.
  • Select treatment for patients with RRMS or progressive MS based on the latest clinical advances, patient risk, and evidence-based recommendations.